Montreal Chest Institute

Montreal, Quebec H4A 3J1

0 studies enrolling now · 14 studies all time

What they study most

Asthma, Cytomegalovirus Infections, Cytomegalovirus Retinitis, HIV Infections, Mycobacterium Avium-intracellulare Infection, Severe Asthma, Tuberculosis, Tuberculosis, Pulmonary

Studies at this site

• TBTC Study 26 PK: Rifapentine Pharmacokinetics in Children During Treatment of Latent TB Infection — Completed
• A Randomized Trial of the Efficacy and Safety of a Strategy of Starting With Nelfinavir Versus Ritonavir Added to Background Antiretroviral (AR) Nucleoside Therapy in HIV-Infected Individuals With CD4+ Cell Counts Less Than or Equal to 200/mm3 — Completed
• Bronchial Thermoplasty in Severe Persistent Asthma — Completed
• Bronchial Thermoplasty 10+ Year Study — Completed
• A Comparison of Valganciclovir and Ganciclovir in the Treatment of Cytomegalovirus (CMV) of the Eyes — Completed
• Phase II Study of AGS-004 as an Immunotherapeutic in Antiretroviral Therapy (ART)-Treated Subjects Infected With HIV — Completed
• TBTC Study 28: Moxifloxacin Versus Isoniazid for TB Treatment — Completed
• Safety and Effectiveness of a New Protease Inhibitor, BMS-232632, in HIV-Positive Patients Who Have Received Previous Treatment — Completed
• A Study of Valacyclovir Hydrochloride in the Prevention of Life-Threatening Cytomegalovirus Disease in HIV-Infected Patients — Completed
• A Phase III Study Comparing Two Different Anti-HIV Drug Combinations in HIV-Positive Patients Without Previous Anti-HIV Drug Therapy — Completed
• A Study to Compare Two Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Previously Received Anti-HIV Treatment — Completed
• TBTC Study 27: Moxifloxacin vs Ethambutol for TB Treatment — Completed
• Effectiveness of a New Anti-HIV Drug (AG1549) Plus Viracept (Nelfinavir) Plus Combivir (Zidovudine/Lamivudine) in HIV-Infected Patients — Paused
• Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in AIDS Patients With CD4 Counts = or < 200: A Double-Blind, Placebo-Controlled Trial — Completed